GlassScriptPhysician profile
Hutton P Brantley
NPI 1558540864
$28,372.05
in general payments reported to CMS, 2019-2025
44 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,862 · 2020: $12K · 2021: $2,080 · 2022: $4,815 · 2023: $754 · 2024: $924 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17,283.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $4,152.03 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $960.43 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $854.24 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $575.23 | 2019-2024 | |
| Amgen INC. | $557.90 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $495.93 | 2020-2025 | Opsumit, Uptravi |
| Pfizer INC. | $392.92 | 2019-2025 | |
| Amarin Pharma, INC. | $380.70 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $271.65 | 2019-2025 | Camzyos, Eliquis |
| Preventice Services, LLC | $187.48 | 2020-2021 | |
| Akcea Therapeutics, INC. | $179.59 | 2019-2021 | |
| Boston Scientific Corporation | $161.13 | 2019-2025 | Eluvia, Ekosonic |
| Philips North America LLC | $153.73 | 2019-2020 | |
| Lundbeck LLC | $152.55 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $149.83 | 2019-2022 | |
| Abbott Laboratories | $139.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.17 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $137.39 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.86 | 2022-2025 | Lifevest |
| Inari Medical, INC. | $93.92 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $81.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.44 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $67.87 | 2021-2025 | Amvuttra |
| Medtronic, INC. | $48.82 | 2022-2023 | Onyx Frontier |
| Irhythm Technologies, INC. | $47.28 | 2019-2023 | Zio Xt Patch |
| Novo Nordisk INC | $46.50 | 2025 | Wegovy |
| Medtronic Vascular, INC. | $45.67 | 2020 | |
| Edwards Lifesciences Corporation | $45.23 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lexicon Pharmaceuticals, INC. | $41.85 | 2024 | |
| Chiesi USA, INC. | $41.71 | 2019-2024 | Kengreal |
| Biosense Webster, INC. | $40.34 | 2025 | Octaray Mapping Catheter |
| Abiomed | $35.73 | 2022 | |
| Amryt Pharma Holdings LTD | $31.50 | 2021 | |
| Angiodynamics, INC. | $29.70 | 2025 | Alphavac |
| Sobi, INC | $29.37 | 2021 | |
| Bridgebio Pharma, INC. | $29.36 | 2025 | Attruby |
| Scpharmaceuticals INC. | $26.11 | 2023 | |
| Arbor Pharmaceuticals, INC. | $23.84 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $17.83 | 2021 | |
| Atricure, INC. | $17.25 | 2025 | Atriclip Laa Exclusion System |
| Bard Peripheral Vascular, INC. | $16.31 | 2021 | |
| Cardiovascular Systems INC. | $13.13 | 2019 | |
| Surmodics, INC. | $7.18 | 2024 | Pounce Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Pounce Venous Thrombectomy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hutton Brantley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.